Reply to Greg Shaw, John D. Kelly, and Monique J. Roobol's Letter to the Editor re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes After Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023;388:1547-58.
Journal article
Hamdy FC. and Donovan JL., (2023), Eur urol
Reply to Bernardo Rocco and Maria Chiara Sighinolfi's Letter to the Editor re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023;388:1547-58.
Journal article
Hamdy FC. and Donovan JL., (2023), Eur urol
Endemic statistical paradoxes in epidemiologic studies distort knowledge on prostate cancer: mitigation and caution of fallacies in prostate cancer causal epidemiological studies.
Journal article
Cussenot O. et al, (2023), Curr opin urol
Genomic Evolution and Transcriptional Changes in the Evolution of Prostate Cancer into Neuroendocrine and Ductal Carcinoma Types.
Journal article
Rao SR. et al, (2023), Int j mol sci, 24
Aligning germline and somatic mutations in prostate cancer. Are genetics changing practice?
Journal article
Cussenot O. et al, (2023), Bju int
Fifteen-Year Outcomes of the ProtecT Trial for Localized Prostate Cancer. Reply.
Journal article
Hamdy FC. and Donovan JL., (2023), N engl j med, 389
Impact of PSA testing on secondary care costs in England and Wales: estimates from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP).
Journal article
Thorn JC. et al, (2023), Bmc health serv res, 23
Clinical performance of magnetic resonance imaging and biomarkers for prostate cancer diagnosis in men at high genetic risk.
Journal article
Cussenot O. et al, (2023), Bju int, 131, 745 - 754
Protocol for the TRANSLATE prospective, multicentre, randomised clinical trial of prostate biopsy technique.
Journal article
Bryant RJ. et al, (2023), Bju int, 131, 694 - 704
Rbf/E2F1 control growth and endoreplication via steroid-independent Ecdysone Receptor signalling in Drosophila prostate-like secondary cells.
Journal article
Sekar A. et al, (2023), Plos genet, 19
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer
Journal article
Hamdy FC. et al, (2023), New england journal of medicine
Patient-Reported Outcomes 12 Years after Localized Prostate Cancer Treatment
Journal article
Donovan JL. et al, (2023), Nejm evidence
Intermediate-risk Prostate Cancer-A Sheep in Wolf's Clothing?
Journal article
Heidegger I. et al, (2023), Eur urol oncol, 6, 103 - 109
Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial.
Journal article
Keeney E. et al, (2022), Pharmacoeconomics, 40, 1207 - 1220
The architecture of clonal expansions in morphologically normal tissue from cancerous and non-cancerous prostates.
Journal article
Buhigas C. et al, (2022), Mol cancer, 21
Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study).
Journal article
Lane JA. et al, (2022), Bju int, 130, 370 - 380
Feasibility and safety of radical prostatectomy for oligo-metastatic prostate cancer: the Testing Radical prostatectomy in men with prostate cancer and oligo-Metastases to the bone (TRoMbone) trial.
Journal article
Sooriakumaran P. et al, (2022), Bju int, 130, 43 - 53
Automated quality assessment of large digitised histology cohorts by artificial intelligence.
Journal article
Haghighat M. et al, (2022), Sci rep, 12